1. D10 Pharmacodynamic Biomarkers For Selisistat: The Paddington Project. (17th September 2014) Authors: Pollio, G; Massai, L; Diamanti, D; Magnoni, L; Westerberg, G; Farmer, RE; Frost, C; Tabrizi, SJ; Landwehrmeyer, GB; Thomas, R Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 85(2014)Supplement 1 Page Start: A34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. F02 Selisistat: soluble HTT protein levels as a potential pharmacodynamic readout. (29th August 2012) Authors: Westerberg, G; Massai, L; Magnoni, L; Pollio, G; Tripepi, G; Diodato, E; Caricasole, A; Bernocco, S; Tabrizi, SJ; Landwehrmeyer, B Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 1 Page Start: A21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. F04 Selisistat: potential pharmacodynamic readouts based on transcriptomics. (29th August 2012) Authors: Westerberg, G; Diamanti, D; Pollio, G; Mori, E; Fondelli, C; Morena, E; Magnoni, L; Tarditi, A; Malusa, F; Tabrizi, SJ; Landwehrmeyer, B; Caricasole, A Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 1 Page Start: A22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FROM BIOLOGY TO THE BEDSIDE-SIRTUINS AS TARGETS FOR DISEASE MODIFICATION IN HUNTINGTON'S DISEASE: SELISISTAT PRECLINICAL DATA AND PRELIMINARY PHASE I RESULTS. (29th November 2012) Authors: Haider, SS; Landwehrmeyer, BG; Sissumuth, SD; Frost, C; Farmer, R; Andre, R; Caricasole, A; Crauford, DI; Westerberg, G; Tabrizi., SJ Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 2 Page Start: A33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. N02 Safety And Tolerability Of Selisistat For The Treatment Of Huntington's Disease: Results From A Randomised, Double-blind, Placebo-controlled Phase Ii Trial. (17th September 2014) Authors: Reilmann, R; Squitieri, F; Priller, J; Saft, C; Mariotti, C; Süssmuth, SD; Nemeth, AH; Tabrizi, SJ; Quarrell, O; Craufurd, D; Rickards, H; Rosser, A; Darpo, B; Tessari, M; Szynol, A; Fischer, DF; Frost, C; Farmer, RE; Landwehrmeyer, GB; Westerberg, G Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 85(2014)Supplement 1 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Q01 SIRT 1 mediated modulation of circulating cytokines in huntington's disease- pharmacodynamics results from phase 1B study of selisistat—A SIRT 1 inhibitor. (29th August 2012) Authors: Haider, S; Andre, R; Farmer, R; Süssmuth, S; Frost, C; Bjorkqvist, M; Westerberg, G; Landwehrmeyer, B; Tabrizi, SJ Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 1 Page Start: A54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Q02 A randomised, double-blind, placebo-controlled phase IB pharmacodynamic study with selisistat (SEN0014196) in HD patients. (29th August 2012) Authors: Süssmuth, SD; Landwehrmeyer, GB; Tabrizi, SJ; Andersen, C; DiBacco, M; Tripepi, G; Westerberg, G Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 1 Page Start: A55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗